Want to see CRSP full AI Analyst Report?
CRSP Stock Chart & Stats
$46.54
-$0.99(-2.08%)
At close: 4:00 PM EDT
$46.54
-$0.99(-2.08%)
Day’s Range― - ―
52-Week Range$44.12 - $78.48
Previous CloseN/A
Volume1.39M
Average Volume (3M)1.68M
Market Cap
$4.63B
Enterprise Value$2.91K
Total Cash (Recent Filing)$2.36B
Total Debt (Recent Filing)$783.75M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Nov 04, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.76
Shares Outstanding96,448,790
10 Day Avg. Volume1,726,236
30 Day Avg. Volume1,677,481
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.45
Price to Sales (P/S)1343.50
P/FCF Ratio-13.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$74.46Price Target Upside59.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.85
Revenue Forecast (FY)$40.93M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthCRISPR Therapeutics’ balance sheet retains sizable equity relative to debt, providing a structural cushion to fund clinical programs and operations. This financial flexibility reduces short-term insolvency risk, enables continued R&D investment, and supports execution across multi-year development timelines.
Commercial Momentum (CASGEVY)Pediatric FDA approval for CASGEVY and a Q2 revenue beat reflect tangible commercial progress for the exa-cel program. Broader label and early revenue demonstrate market access and cadence of partnered economics, which can create recurring product-linked cash flow and de-risk future milestone timing.
Pipeline Expansion And Platform DiversificationInitiation of Phase 1 studies for CTX340 and CTX460 signals platform applicability to in vivo targets and expands therapeutic breadth beyond hematology. Diversifying indications across modalities and diseases increases long-term upside probability and reduces reliance on a single asset for future value creation.
Bears Say
Sustained Cash BurnTrailing-twelve-month operating and free cash flow are materially negative with deterioration versus prior year, indicating persistent cash burn. This ongoing funding gap creates multi-quarter financing needs, which can force dilution or higher-cost capital and constrain long-term program pacing.
Volatile, Negative ProfitabilityThe income statement shows negative gross profit and large operating and net losses with high volatility over time. That uneven earnings base undermines margin sustainability, complicates planning for durable profitability and increases reliance on milestone and partner payments to reach positive economics.
Rising Leverage And Dilution RiskShareholder approval of an expanded incentive plan and increases to capital/conditional share capital broaden issuance capacity. Coupled with rising TTM leverage, this structural flexibility raises the probability of future equity issuance or convertibles to fund operations, diluting existing holders and raising capital costs.
Crispr Therapeutics AG News
CRSP FAQ
What was Crispr Therapeutics’s price range in the past 12 months?
Crispr Therapeutics lowest stock price was $44.12 and its highest was $78.48 in the past 12 months.
What is Crispr Therapeutics’s market cap?
Crispr Therapeutics’s market cap is $4.63B.
When is Crispr Therapeutics’s upcoming earnings report date?
Crispr Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 91 days.
How were Crispr Therapeutics’s earnings last quarter?
Crispr Therapeutics released its earnings results on Aug 03, 2026. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.195 by $0.255.
Is Crispr Therapeutics overvalued?
According to Wall Street analysts Crispr Therapeutics’s price is currently Undervalued.
Does Crispr Therapeutics pay dividends?
Crispr Therapeutics does not currently pay dividends.
What is Crispr Therapeutics’s EPS estimate?
Crispr Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does Crispr Therapeutics have?
Crispr Therapeutics has 96,448,790 shares outstanding.
What happened to Crispr Therapeutics’s price movement after its last earnings report?
Crispr Therapeutics reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.195. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Crispr Therapeutics?
Currently, no hedge funds are holding shares in CRSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crispr Therapeutics AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$74.46 (59.99% Upside)
$74.46 (59.99% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 88%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 668.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.84%
Trailing 12-Months
Company Description
Crispr Therapeutics
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
CRSP Stock 12 Month Forecast
Average Price Target
$74.46
▲(59.99% Upside)
Technical Analysis
Ownership Overview
2.54% Insiders
13.62% Mutual Funds
3.11% Other Institutional Investors
61.61% Public Companies and Individual Investors